Altre lingue Satellos Bioscience Inc.

Azioni

MSCL

CA80401L3083

Mercato chiuso - Toronto S.E. Altri mercati azionari 21:17:00 10/05/2024			Variaz. 5gg	Var. 1 gen.
0,47 ^CAD	+2,17%		+17,50%	+9,30%

27/03	Satellos Bioscience Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI
27/03	Satellos Bioscience annuncia i risultati dell'esercizio 2023	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	08/04
Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Satellos Bioscience: Q4 Earnings Snapshot	27/03
Satellos Bioscience Announces FY 2023 Results	27/03
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights	27/03
Satellos to Present at Upcoming Virtual Investor Conferences in March and April	14/03
Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024	05/03
Satellos Presented "Positive" Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	04/03
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	04/03
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	04/03
Satellos Recognized as a Top 50 TSX Venture Exchange Company	21/02
Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	20/02
Satellos Bioscience Inc. Brief: Says Will commence trading on the Toronto Stock Exchange as of the opening of trading tomorrow	14/02
Satellos to Commence Trading on the Toronto Stock Exchange	14/02
Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy	13/02
Satellos Bioscience Inc. Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy	13/02
Satellos Announces Management Team Update	24/01
Satellos Bioscience Inc. Brief: Shares Jumped 13.4% on Monday; Co Recently Received Conditional Approval to Graduate to the Toronto Stock Exchange	23/01
Satellos Bioscience Inc. Brief: Announced Earlier Tuesday Management Team Update; Alan K. Jacobs, Chief Medical Officer Has Left to Pursue Other Opportunities; Jordan Dubow Engaged As Chief Medical Advisor	23/01
Satellos Bioscience Inc. Announces Executive Changes	23/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Satellos Bioscience Inc.

Azioni

MSCL

CA80401L3083

Altre lingue

Filtri